CHOP Breakapart Probe LPS015 - Detail

Myxoid liposarcoma (MLS) is the most common subtype of liposarcoma¹. The TLS-CHOP t(12;16)(q13;p11) fusion gene firstly described by Turc-Carel et al. in 1986², is now well established and present in at least 95% of MLS³. In rare cases a EWS-CHOP t(12;22)(q13;q12) translocation has been described⁴. The transcription factor gene, CHOP (DDIT3) (CREBPhomologous protein/DNA damage inducible transcript 3) is a negative regulator of adipocyte differentiation⁵. The TLS (Translocated in Liposarcoma)⁶ or FUS⁷ is a nuclear RNA-binding protein with extensive sequence similarity to EWS. The TLS-CHOP protein interferes with adipocyte differentiation and favours proliferation over terminal differentiation.

Reference:/Bibliographie/Literatur/Bibliografia

1. Enzingher and Weiss 1995 Soft Tissue Tumors Ed. 3. St Louis; C.V.Mosby
2. Turc-Carel et al 1986 Can. Genet. Cytogenet. 23:291-299
3. Mitelman 1995 Catalog of chromosome aberrations in cancer Ed. 5. New York: WileyLiss, Inc., 1994
4. Antonescu et al 2000 Clin. Canc. Res. 7:3977-3987
5. Ron and Habener 1992 Genes Dev., 6:439-453
6. Crozat et al 1993 Nature, 363:640-444
7. Rabbitts et al 1993 Nat. Genet., 4:175-180